Anika Therapeutics, Inc. Impairment of Intangible Assets, Finite-lived
Anika Therapeutics, Inc. (ANIK) reported Impairment of Intangible Assets, Finite-lived of $2.46 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2025-03-17
- Anika Therapeutics, Inc. impairment of intangible assets, finite-lived for the quarter ending 2024-12-31 was $1.30M, a 94.09% decline year-over-year.
- Anika Therapeutics, Inc. impairment of intangible assets, finite-lived for the quarter ending 2023-12-31 was $22.03M.
- Anika Therapeutics, Inc. impairment of intangible assets, finite-lived for the quarter ending 2023-09-30 was $1.95M.
- Anika Therapeutics, Inc. impairment of intangible assets, finite-lived for the quarter ending 2023-06-30 was $1.95M.
- Anika Therapeutics, Inc. impairment of intangible assets, finite-lived for fiscal 2024 was $2.46M, a 96.04% decline from fiscal 2023.
- Anika Therapeutics, Inc. impairment of intangible assets, finite-lived for fiscal 2023 was $62.19M.
- Anika Therapeutics, Inc. impairment of intangible assets, finite-lived for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Anika Therapeutics, Inc. impairment of intangible assets, finite-lived for fiscal 2021 was $600.00K, a 75.40% decline from fiscal 2020.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $2.46M 10-K · filed 2025-03-17 | ||
| 2024-09-30 | $1.16M 10-Q · filed 2024-11-04 | |||
| 2023-12-31 | $22.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $23.98M derived: sum of 2 quarters · filed 2025-03-17 | $25.93M derived: sum of 3 quarters · filed 2025-03-17 | $62.19M 10-K · filed 2025-03-17 |
| 2023-09-30 | $1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $3.89M derived: sum of 2 quarters · filed 2023-11-03 | $40.16M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $38.21M 10-Q · filed 2023-08-08 | ||
| 2023-03-31 | $36.27M 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-17 | |||
| 2021-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $600.00K derived: sum of 2 quarters · filed 2024-03-15 | $600.00K derived: sum of 3 quarters · filed 2024-03-15 | $600.00K 10-K · filed 2024-03-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | $1.41M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | $1.41M derived: sum of 3 quarters · filed 2023-03-16 | $1.41M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | $1.41M derived: sum of 2 quarters · filed 2023-03-16 | $1.41M derived: sum of 3 quarters · filed 2023-03-16 | $2.12M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.41M derived: sum of 2 quarters · filed 2023-03-16 | $2.12M derived: sum of 3 quarters · filed 2023-03-16 | $2.44M 10-K · filed 2023-03-16 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $707.00K derived: sum of 2 quarters · filed 2021-11-05 | $1.02M 10-Q · filed 2021-11-05 | $1.11M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | $707.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $1.02M 10-Q · filed 2021-08-06 | $1.11M derived: sum of 3 quarters · filed 2022-03-11 | $1.13M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-03-31 | $318.00K 10-Q · filed 2021-05-07 | $404.00K derived: sum of 2 quarters · filed 2022-03-11 | $426.00K derived: sum of 3 quarters · filed 2022-03-11 | $426.00K derived: sum of 4 quarters · filed 2022-03-11 |
| 2019-12-31 | $86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $108.00K derived: sum of 2 quarters · filed 2022-03-11 | $108.00K derived: sum of 3 quarters · filed 2022-03-11 | $389.00K 10-K · filed 2022-03-11 |
| 2019-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $22.00K derived: sum of 2 quarters · filed 2020-11-05 | $303.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $281.00K 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $281.00K 10-Q · filed 2020-05-22 | |||
| 2018-12-31 | $0.00 10-K/A · filed 2021-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |